Clinical Trial Update: TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients [Phase 3]

View source ↗

Summary

Phase 3 trial TMC114-C214 assessed TMC114 (darunavir) with low-dose ritonavir in treatment-experienced HIV-1-infected patients; the study was completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Ritonavir (Ritonavir)
• TMC114 (darunavir)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV Infection | Phase 3 | Status: COMPLETED